Home / コンテンツ / オンデマンド・ウェビナー / Sealing Pharma Commercialization Deals: Creating Optimal Value for Investors
Sealing Pharma Commercialization Deals: Creating Optimal Value for Investors
オンデマンド・ウェビナー

It is crucial for biotech developers to engage in early commercial market assessment to generate value for Regulators, Payers, and Clinicians. This approach should be integrated with a clinical development strategy that will help drive acquisition potential, co-development prospects, and overall return on investment.

Speakers:

Fran Brown

Dr. Fran Brown is currently the SVP of Drug Development Services in Certara’s Integrated Drug Development Division. She is a highly respected professional with proven leadership skills and 25 years of broad experience within pharmaceutical development and due diligence/asset evaluation. Fran possesses a broad knowledge of strategic drug discovery and development, with a special focus on development strategy and the application of Model Informed Drug Development.

Oliver Leatham

Oliver Leatham is the Global Market Access Head for Certara, with over 20 years specializing in the European Market Access landscape. Oliver has worked for both pharmaceutical manufacturers and in consultancy, with significant experience in integrating Global product strategies with local market needs, ensuring that clinical programs meet with commercial ROIs. He is a thought-leader in this difficult to navigate arena, with several well-known examples of successful positive appraisals, subsequent reimbursement and commercial return achieved. Oliver has sat on the AWMSG (Wales), speaks regularly at EU Market Access Summits (such as ISPOR) and writes for publications, such as the Harvard Business Review.

トップに戻る
Powered by Translations.com GlobalLink OneLink Software